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   Abstract  
Introduction: In this study, we report on initial efforts to discover putative biomarkers for differential diagnosis of a systemic inflammatory
response syndrome (SIRS) versus sepsis; and different stages of sepsis. In addition, we also investigated whether there are proteins that can
discriminate between patients who survived sepsis from those who did not. Materials and Methods: Our study group consisted of 16
patients, of which 6 died and 10 survived. We daily measured 28 plasma proteins, for the whole stay of the patients in the ICU. Results: We
observed that metalloproteinases and sE-selectin play a role in the distinction between SIRS and sepsis, and that IL-1α, IP-10, sTNF-R2 and
sFas appear to be indicative for the progression from sepsis to septic shock. A combined measurement of MMP-3, -10, IL-1α, IP-10, sIL-2R,
sFas, sTNF-R1, sRAGE, GM-CSF, IL-1β and Eotaxin allows for a good separation of patients that survived from those that died (mortality
prediction with a sensitivity of 79% and specificity of 86%). Correlation analysis suggests a novel interaction between IL-1a and IP-10.
Conclusion: The marker panel is ready to be verified in a validation study with or without therapeutic intervention
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   Introduction  
A consensus conference in 1992 first published agreed-upon definitions of systemic inflammatory response syndrome (SIRS), sepsis (SIRS
with known or suspected infection), severe sepsis and septic shock. [1] With these operational definitions in hand, statistics on incidents have
been collected and have established that sepsis is the tenth leading cause of death in the USA with over 700 000 cases a year and with
mortality rates above 30%. [2] The incidents continue to increase, with unacceptably high mortality rates, despite the use of a wide variety of
therapies and continuing research. 
During the onset of sepsis, a massive inflammatory reaction occurs in the initial phase, which is followed by a variable anti-inflammatory
response. [3] These events involve chemical mediators, such as cytokines and chemokines, and inflammatory cells, such as the
polymorphonuclear neutrophils and macrophages. Therefore, inflammatory as well as anti-inflammatory biomarkers could potentially be used
for diagnosis and outcome prediction. Moreover, such biomarkers may stimulate evidence-based medicine, the design of preventive clinical
approaches as well as personalized treatment protocols. As our first effort in this direction, we analyzed a dataset consisting of 28 plasma
proteins collected from patients during their stay in an intensive care unit (ICU). The following clinically relevant aspects were addressed:
differential diagnosis of SIRS versus sepsis;
sepsis disease severity and
the outcome (survival or death due to sepsis).
In this study, we demonstrate the relevance of MMP-1, -2, -7, -13 and sE-selectin for the distinction between SIRS and sepsis. The down
modulation of MMPs may be relevant to facilitate receptor re-expression, which was impaired in an infection-independent systemic
inflammation (SIRS). Further, we identified a set of biomarkers related to sepsis disease severity. These were IL-1α related to apoptosis and
inflammation, IP-10 related to leukocyte recruitment into inflamed organs and sTNF-R2 and sFas related to a pro-inflammatory environment
with little beneficial effect on functional modulation of the sepsis scenario.
   Materials and Methods  
Patient population
Sixteen ICU patients were included in this prospective study and recorded daily over 4-15 days. All patients were surgical patients:
polytraumatized, after abdominal, lung and great vessel surgery. From admission to ICU to discharge from the ICU, we aggregated clinical
data into the following scores: 
SAPS II (Simplified Acute Physiological Score II): 17 variables (12 physiological variables, age, admission for medical or
scheduled/unscheduled surgery and underlying diagnosis (acquired immunodeficiency syndrome, metastatic cancer, hematologic
malignancy)). [4]
SOFA (Sequential Organ Failure Assessment) score: status of six organ systems (respiration, coagulation, liver, cardiovascular,
central nervous system, renal).  [5]
Sepsis score: graded, based on the international sepsis definitions, as: (1) local infection, (2) bacteremia, (3) SIRS, (4) sepsis, (5)
severe sepsis, (6) septic shock. [1]
Sepsis was defined using the original 1992 ACCP/SCCM sepsis definitions. [1] In the present study, due to the 1992 definitions, a systemic
inflammatory response syndrome (SIRS) was manifested in patients by two or more of the four conditions: temperature >38°C or <36°C, heart
rate >90/min, respiratory rate >20/min or PaCO 2 <32 torr and white blood cell count (WBC) >12 000 cells/mm
 3 or <4000 cells/mm 3 . If SIRS
was due to a documented infection, patients were classified as sepsis patients. Severe sepsis was defined as sepsis plus organ dysfunction.
Septic shock was defined as severe sepsis plus shock. Severity of sepsis is proposed to increase firstly by association with organ
dysfunctions and secondly by additional shock. As recommended, in the present study, applying the 1992 sepsis definitions, organ failure was
regarded to be present if patients had lactic acidosis or oliguria, or reached greater than two points in one organ system (lung, coagulation,
liver, kidney) using the SOFA score. [5] Greater than two points are reached in the SOFA score for the organ system lung with PaO 2 /FiO 2
≤200 with respiratory support, for coagulation with platelets ≤50 000/μl, for liver with bilirubin >6 mg/dl or 102 μmol/l, for kidney with creatinine
>3.5 mg/dl or >300 μmol/l or with urine output <500 ml/day. Septic shock was defined as hypotension despite adequate volume resuscitation,
a systolic blood pressure of ≤90 mmHg or the need of vasopressors to keep blood pressure >90 mmHg. [1] 
In total, 118 samples were collected from the abovementioned 16 patients. Six of these patients died, and 10 survived. In addition to these 16
patients, four healthy volunteers of the same age without SIRS or sepsis were included in the study, each contributing one plasma sample.
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In the plasma samples, 28 biomolecules were analysed using the Luminex system (USA): 10 cytokines (TNF-α , IL-1β, Eotaxin, IL-13, MIP-
1α, IL-10, IL-1α, IP-10, GM-CSF and IFN-γ ), 8 matrix metalloproteinases (MMP-1, -2, -3, -7, -8, -9, -10 and -13) and 10 soluble(s) factors
(GP130, IL-2R, ICAM, E-selectin, Fas, TNF-R1, TNF-R2, RAGE, VCAM and MIF). The inter- and intra-assay variation was <10% (data not
shown). The choice for the abovementioned biomolecules is motivated as follows. Inflammation caused by tissue damage (SIRS) is primarily
mediated by activation of the inflammasome - consecutively raising IL-1β, TNF-α in the tissue. Theses cytokines cause the release of soluble
TNF-receptors. In the plasma, soluble TNF-R2 appears to be more sensitive than sTNF-R1. In the infection-associated inflammation, TLR
activation may be responsible for the induction of IFN-γ, as well as NF-kB-guided cytokines such as TNF-α, IL-8, IL-6, etc. some of which
may be rapidly bound by receptors and are sensitive to detection assays using two monoclonal antibodies such as multiplexed bead
associated assays. Generally, inflammation causes activation of many proteases and metalloproteases, which are either beneficial by
degrading matrix proteins or are detrimental by cleaving receptors and contribute to anergy and non-responsiveness that appears to be a key
factor in sepsis-associated pathogenesis. Finally, we chose soluble receptors to be determined since these biomarkers indicate which
receptors are regulated in a defined disease state. Soluble iCAM, for instance, indicates whether transendothelial migration is one of the
major processes going on at a defined time point. In a third aspect, we questioned the contribution of macrophages in the inflammatory
process. Monocytes often disappear from the peripheral leukocyte population in patients with major SIRS or sepsis and we believe that they
go to tissues. We chose MIP-1α to assess functional macrophage activity.
Analysis methods
ANOVA analysis
We performed an ANOVA on each biomolecule to discover differences among the four disease codes (3-SIRS, 4-sepsis, 5-severe sepsis, 6-
septic shock). The distributions of measured values were not close to a normal distribution (assumed by ANOVA), so the data were log
transformed before analysis. The numbers of observations available varied due to different lengths of the patients' stay at the ICU. As shown
in [Table 1], some patients have many observation days with septic shock (such as patients #8 and #10), whereas others have observation
days with SIRS only (patient #9). Four patients (#2, #5, #11 and #14) had days with SIRS and days with some form of sepsis, with patients
#2, #5 and #14 first having some form of sepsis, and later have SIRS, and patient #11 starts with SIRS, which later turned into severe sepsis,
and had SIRS again on the last day. Note that a patient can go from sepsis to SIRS if (s)he is successfully treated, as then microorganisms
and infection may no longer be proven and hence the sepsis criteria are no longer met, while the criteria for SIRS can still be fulfilled.
Unfortunately, no design could be found that permitted the rigorous separation of the patient and day effects. We therefore treated each
observation as independent, but adjusted the degrees of freedom of the F test to correct for these effects. Bonferroni correction was used to
correct for the multiple tests, as we test 28 biomolecules simultaneously.
Correlation analysis
Next, as a second step we performed a correlation analysis and computed the Pearson correlation between the log-transformed
measurements of each of the biomolecules on the one hand, and each of the following eight labels on the other:
SIRS (code 3) versus sepsis (code 4);
SIRS (code 3) versus sepsis, severe sepsis and septic shock (codes 4, 5, 6);
sepsis (code 4) versus severe sepsis and septic shock (codes 5, 6);
sepsis (code 4) versus septic shock (code 6);
sepsis (code 4) versus severe sepsis (code 5);
the SOFA score;
the SAPS II score and
the outcome (survival/death).
As a reference, to determine the significance level for each of the computed correlations, we determined what correlations can be obtained by
chance, by randomly permuting each label 10 000 times and computing the correlation to each of the biomolecules. In this way, we obtained
expected correlations and variances, which we used to compute P  -values. In addition, we again applied the Bonferroni-correction for multiple
testing. Note again that the obtained P -values are biased, as we treated each sample as independent, whereas these come from a limited
number of patients.
Pattern recognition analysis
In a third step, we performed a search for combinations of biomolecules that could give rise to a classifier to distinguish SIRS (code 3) from
the septic condition (code 4). The idea was to see if a diagnostic biomarker set might be identified to distinguish sepsis from SIRS conditions.
For this, a genetic algorithm [6] especially devised for subset selection was used. To identify small subsets of these biomolecules that would
make the desired distinction, a support vector machine was trained on some of the observations and then tested on others. Because of
missing data issues, six biomolecules were discarded (MMP-3, -7, IL-13, IFN-γ, sE-selectin and sVCAM). The final learning set consisted of
34 observations, 20 in SIRS and 14 in sepsis, from 10 patients among whom only patient #2 contributed observations to both conditions (see
[Table 1]). Because of the stochastic nature of both the genetic search and the training of candidates on differing sets of observations, 10
independent searches were performed. Approximately two-thirds of the available observations were used for training and all were used for
testing.
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Prediction SIRS versus sepsis and predicting outcome
In a fourth step, we developed rules for predicting SIRS versus sepsis and for predicting mortality, and we generated the corresponding
receiver operating characteristic (ROC) curves.
For predicting SIRS (code 3) versus sepsis (code 4), we took the individual biomolecules that we identified in the previous two steps, and
simply used a threshold rule, i.e. above a certain threshold the patient's sample is classified as sepsis, and below it the sample is classified as
SIRS. By varying the threshold, we created an ROC curve.
For predicting mortality, we applied a naïve Bayesian classifier,  [7] using the panel of biomolecules that were identified to correlate
significantly to the outcome. We applied a leave-one-out scheme, i.e., the classification of each sample is done by a classifier that is trained
on the set of samples not including the particular sample at hand. By varying the classification threshold on the posterior probability, we again
created an ROC curve. We also calculated sensitivity and specificity for the default threshold level and plotted the correctness of mortality
prediction for the different patients and for their different days during the ICU stay. When making mortality predictions for new samples, the
Bayesian classifier can be trained on all samples from this study, and directly applied to the measurements of the new samples.
Correlations between biomolecules 
The final analysis was to compute the Pearson correlation between the log measurements for each pair of biomolecules. 
   Results and Discussion  
Results of the experiments
ANOVA analysis
The results of the ANOVA showed that MMP-1, -2, -7, -13 and sE-selectin are significantly lower in septic cases than in SIRS cases.
Furthermore, IP-10, sFas and sTNF-R2 were elevated most in the plasma of patients in septic shock. Corresponding P-values after
Bonferroni correction are below 0.01. We have to note, though, that these results may still contain the confounding of patients with sepsis
state (see discussion). [Figure 1] and [Figure 2] show the ranges of the log measurements for the above-described biomolecules.
Correlation analysis
The correlation analysis resulted in the following findings.
MMP-1, -2, -7 and -13 plasma concentrations showed to be significantly lower ( P  < 0.001) in sepsis (code = 4) as compared to SIRS
(code = 3), with absolute correlation values ~0.8.
In addition to these four, IL-1α, IP-10 and sTNF-R2 were higher (P  < 0.05) in sepsis, severe sepsis and septic shock (codes = 4, 5,
6) as compared to SIRS (code = 3).
sFas and sTNF-R2 were higher ( P  < 0.05) in severe sepsis and septic shock (codes = 5, 6) as compared to sepsis (code = 4) and
also in septic shock (code = 6) as compared to sepsis (code = 4).
MMP-2, MMP-7 and IL-1β were negatively correlated to the SAPS II score (P  < 0.01) and MMP-3, IL-1α, IP-10, sFas, sTNF-R1 and
sTNF-R2 were positively correlated to the SAPS II score (P < 0.001). The correlation of sTNF-R1 was relatively high (0.78).
Many biomolecules were correlated with the SOFA score ( P  < 0.01), with however slightly lower absolute correlations (up to 0.50).
MMP-2, -7, IL-1β, Eotaxin, GM-CSF and IFN-γ were negatively correlated, and MMP-3, -8, -10, IL-10, IP-10, sFas, sTNF-R1 and
sTNF-R2 were positively correlated.
The patients who died from septic complications had elevated levels of MMP-3, -10, IL-1α, IP-10, sIL-2R, sFas, sTNF-R1, sTNF-R2
and sRAGE as compared to the surviving patients (P< 0.05). In contrast, the former patients showed low levels of GM-CSF, IL-1β
and Eotaxin (P < 0.05).
Pattern recognition analysis
[Table 2] shows the set of best-performing classifiers. Each line in the table gives a biomarker set (consisting of two or three biomolecules),
and the associated performance in terms of average number of errors over the 10 independent runs, and the maximum error over the 10
runs.
We note that in no case did any of these classifiers make an average (over the 10 runs) worse than 2 errors out of a possible 34. We see the
MMPs are strongly being represented. Half of the errors are contributed by measurements of patient #11 on day 8, while the other half is
contributed by patient #2, the only patient contributing measurements to both the SIRS and sepsis classes. This may be an indication of the
possible confounding of patient effects with the clinical distinction we are seeking.
[Table 2] indicates three strong pairs of compounds: MMP-2 with MMP-8, MMP-8 with MMP-13 and MMP-13 with MIP-1α (although this pair
did not meet our error cutoff without adding a third biomolecule). The role of MIP-1α and MMP-8 is quite striking, as they are in themselves
hardly indicative for being SIRS (code 3) or sepsis (code 4); the correlation analysis indicated that their correlations to that label are quite
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weak. To get more insight, we plotted the log measurements for samples with codes 3 and 4, for each of these three pairs of compounds;
see [Figure 3]. As we can see in the figure, the main separator is MMP-13 in the left and middle graph, and MMP-2 in the right hand graph.
MIP-1α and MMP-8 seem to make the separation only slightly better.
Prediction SIRS versus sepsis and predicting outcome
The ROC curves are shown in [Figure 4]. We see that SIRS can be distinguished from sepsis by using MMP-1, -2, -7, or -13 with an AUC of
more than 0.95 (P  < 2e-6); sE-selectin performs a bit worse, with an AUC of 0.80 (P  < 0.005). For predicting mortality, we see that by using
the panel of biomolecules identified by the correlation analysis, consisting of MMP-3, -10, IL-1α, IP-10, sIL-2R, sFas, sTNF-R1, sTNF-R2,
sRAGE, GM-CSF, IL-1β and Eotaxin, we get a much higher AUC (0.89, P = 3.6e-13) than by using the SAPS II or SOFA score.
[Figure 5] shows the correctness of the mortality prediction for all patients and all their days during his/her ICU stay. We observe that the
predictions are already accurate during the first two days for 12 of the 16 patients (although patient #5 has no measurement on day two), two
patients (#4 and #10) have a wrong prediction on one of the first two days, and two patients (#13 and #15) have wrong predictions on their
both first days. This means that the classifier can be used as an early predictor of mortality. Counting the overall samples, we have 33 true
positive and 9 false negative predictions, giving a sensitivity of 79%. Furthermore, we have 65 true negative and 11 false positive predictions,
giving a specificity of 86%.
Correlations between biomolecules 
The Pearson correlation between the log measurements for each pair of biomolecules is depicted in [Figure 6]. Three groups of strongly
correlating biomarker concentrations appear in the figure:
MMP-1, MMP-2, MMP-7 and MMP-13;
TNF-α, IL-1β, Eotaxin, IL-13 and GM-CSF and
IL-1α and IP-10.
Biological interpretation
MMPs and sE-selectin
When we combined biomolecules that could give rise to a better distinction of SIRS and sepsis, using a genetic algorithm devised for subset
selection, we found the following remarkable biomarker pairs: MMP-13 with MIP-1α (not alone, but combined with either sFas, sGP-130,
sICAM, sIL-2R, sRAGE or sTNF-R2), MMP-2 with MMP-8 and MMP-8 with MMP-13. All of these are related to tissue remodeling and
leukocyte chemotaxis and recruitment. MMP-2 and -13 are also best classifiers for SIRS and sepsis as demonstrated in the biplot in [Figure 3]
and the ROC curves in [Figure 4]. Correlation analysis [Figure 6] shows that MMP-1, -2, -7 and -13 strongly correlate. Out of the inflammatory
cytokine panel IL-1β and TNF-α correlated, which supports the observation that TNF-α is a major inducer of IL-1β in sepsis, which has been
known for a long time.[8] Eotaxin, IL-13 and GM-CSF may play a role in concomitant recruitment of TH2 lymphocytes and myeloid
progenitors including eosinophils, respectively. The correlation of IL-1α and IP-10 detected here is indeed challenging since the
chemoattractant IP-10 is dependent on Interferon-activation and IL-1α is a member of the highly promiscuous cytokine family related to NF-
kB activation. The biomarkers identified are interesting because of arguments based on clinical observations but also based on basic science.
In this study, we provide evidence for a high discriminative value of defined MMPs between SIRS (code = 3) and sepsis (code = 4). Following
[Figure 1] and the ANOVA and correlation analyses, MMP-1, -2, -7, -13 and sE-selectin are higher in SIRS as compared to sepsis. MMP-7
remains low in all stages of sepsis including septic shock. This MMP-7 was found to be significantly lower in patients with an NQO-1 mutation
suggesting that MMP-7 diminution may be related to oxidative stress (Schneider et al., unpublished data). Matrix metalloproteinases are
involved in extracellular matrix remodeling and cell migration that occur following injury or infections. MMP-7 mediates cleavage of E-cadherin
to stimulate transepithelial migration of neutrophils controlling bacterial infections. Studies in mice suggest that MMP-7 also regulates the
antimicrobial activity of defensins in intestinal mucosa. [9] Moreover, MMP-7, the matrilysin cleaves a number of nonstructural proteins, such
as pro-TNF-α and Fas-L,[10] and contributes to the pool of active cytokines and soluble receptors. MMP-1 has been demonstrated to activate
MMP-3 and stimulate tumor cell migration. [11] A previous study by Hoffmann et al. found no differences in the plasma levels of MMP-2
between healthy controls and septic patients. [12] Others found that MMP-2, a type IV collagenase, is present in joints and plasma of healthy
controls but is activated by thrombin, [13] suggesting that sepsis-associated decline of MMP-2 may be due to binding of selective inhibitors or
transcriptional downregulation. The patterns of MMP-1, -2 and -13 are very similar suggesting that these enzymes play a major role in stress-
induced tissue remodeling. [14] Although MMP-9 and -13 may correlate in other studies, we did not find significant differences in the MMP-9
protein levels between SIRS and septic patients. Studies using MMP-9 gene deficient mice (MMP-9-/-) and normal wild-type mice both
infected (i.p) with  Escherichia More Details coli showed that MMP-9 deficient mice displayed a reduced resistance against E. coli, as
indicated by an enhanced bacterial outgrowth in the peritoneal cavity and increased dissemination of infection. [15] 
Next to the decreased levels of MMP in septic patients, we also found decreased levels of sE-selectin. E-selectin is an early mediator of
leukocyte-endothelial adhesion, and is expressed on activated endothelium. [16] In our study, we observed a relatively low E-selectin
secretion into the blood stream as the diseases progressed from SIRS to sepsis. The vascular endothelium controls leukocyte extravasation
into tissue by the induction and modulation of endothelial cell adhesion molecules, such as E-selectin (CD62E). E-selectin is not expressed
by non-stimulated endothelium, but is activated by cytokines and initiates neutrophil recruitment in sepsis-induced lung injury. [17] According
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to our results, soluble E-selectin is an important parameter in the transition of SIRS and sepsis. Specifically, sE-selectin has not been found
to increase with the manifestation of sepsis; it increases in a longitudinal course during severe sepsis. The significance of sE-selectins and
sICAM-1 levels during severe acute stress in children has been described earlier. [18] Cummings et al. [16] studied septic patients as
compared to critically ill medical ICU patients and found an increase of sE-selectin plasma concentrations in sepsis. Unfortunately, in our
study a distinction between sepsis and severe sepsis has not been made [Figure 1]. The age-matched individuals studied as a control
population had elevated sE-selectin concentrations as well; however, these individuals were studied pre-operatively. Results indicate that
biomarkers need to be generally studied in a defined clinical context and may not be specific for a defined disease.
Cytokines
Plasma protein concentrations of IL-1α, IP-10 and sTNF-R2 were higher in septic patients compared to SIRS. Moreover, these markers,
together with sFas were even more elevated in patients with septic shock [Figure 2] suggesting that these biomarkers correlate with staging
septic patients and intensive care. In a study evaluating key cytokines and chemokines in preterm infants, IP-10 with a plasma cutoff
concentration ≥1250 pg/mL could identify all septemic infants with the highest sensitivity (93%) and specificity (89%) at 0 h. [19] IL-1α is a
pleiotropic cytokine related to inflammation and tissue injury.[20] IP-10 is a chemokine, CXCL10, secreted by TH1 lymphocytes upon IFN-γ
stimulation. [21] Binding to CXCR3, IP-10 induces recruitment of T-cells, [22] but also natural killer effectors and dendritic cells. Moreover, IP-
10 is a new member of LPS-responsive cytokines. [23] Recently, the application of IP-10 specific antibodies has been suggested to cure Type
I diabetes. [24] As exemplified by CCR4 deficiency, chemokine receptor deficiency related to leukocyte recruitment may result in improved
survival following septicemia. [25],[26] Upon progression of sepsis, we observed elevated plasma protein concentrations of sTNF-R2 and sFas
(sCD95). Both mediators were correlated to disease severity. In the case of CD95, these results may mean that more CD95 is expressed and
concomitant to increased protease activity, a greater amount of soluble receptor is expected to be released into the circulation. Soluble TNF
receptors are well-recognized to indicate the severity of organ failure [27] and indicate the immune system's attempt to limit pro-inflammation.
In patients with sepsis and acute hepatic failure, a correlation between TNF-α and sFas has been shown.[28] The same study suggested that
sFas-ligand was protective. The selective elevation of sFas in patients with sepsis as compared to SIRS has been shown in adults [29] and
with an even greater impact in pediatric cases substantiating a role for sFas in inflammatory deregulation in severe sepsis. [30] In another
study, it has been demonstrated that the onset of severe sepsis and macrophage apoptosis was rather related to mitochondrial dysfunction
and Hsp70 rather than soluble Fas or Bcl-2. [31] It may be concluded that the results of sFas are directed to organ injury rather than
apoptosis of circulating leukocytes. Indeed, tissue and organ damage leading to multiple organ dysfunctions and death constitute end-stage
parameters in a lethal course of sepsis.
Strengths, limitations and future directions
The strengths of the analysis presented in this paper is to provide information on a reasonably small set of biomarkers selected from the huge
amount of cytokines, chemokines and molecules, which are released upon inflammation. This set of markers bears some that correlate and
others that cooperate to define the severity of disease. Given a certain time point of a patient's course, the designation of clinical scores for
sepsis, SOFA and SAPS II have been established to predict outcome. Unfortunately, none of these scores include immune markers, despite
the fact that patients under intensive care die from immune deficiency and anergy, which classically follow hyper-inflammation.
As exemplified here, the state of blood infections cannot be deduced from scores, however, it can be from immune profiling (see patients #2,
#5, #11 and #14). Since we also included markers indicative for oxidative stress that may have accumulated already before major trauma,
such as sRAGE, the current strategy implements a pre-trauma risk status. 
It may be regarded as a limitation, but it may also be an advantage to include several observations of a single patient's course as
independent event since chronicity of anergy is a characteristic of sepsis and a more dynamic behavior is a characteristic of SIRS.
A major limitation of our current approach remains to be the significance of the biosignature identified. A small number of patients in a fairly
homogenous clinical setting has been followed so far, for practical reasons. More patients would make such a study to become even more
laborious, time consuming and expensive. 
Future directions of biosignatures are to support the predictive value of currently applied clinical scores. We foresee a comprehensive
discussion on individual molecules such as sE-selectin or metalloproteinases to understand the regulation of hyper-inflammation and non-
responsiveness. Although not yet reported for SIRS and sepsis, the most recent relationship between myeloid-derived suppressor cells and
metalloproteinases may be used as a hint into the right direction. [32]
   Conclusion  
In conclusion, the current analysis stresses the relevance of MMP-1, -2, -7, -13 and sE-selectin concentrations for the transition of SIRS to
sepsis. The down-modulation of MMPs may be relevant to facilitate receptor re-expression, which was impaired in an infection-independent
systemic inflammation (SIRS). Further, we identified a set of biomarkers to distinguish between SIRS, sepsis, severe sepsis and septic
shock. These were IL-1α related to apoptosis and inflammation, IP-10 related to leukocyte recruitment into inflamed organs, sTNF-R2 and
sFas related to a pro-inflammatory environment with little effect on a beneficial functional modulation of the sepsis scenario. The feasibility of
multiplex-guided determinations accompanied by documentation of simplified staging may be suitable to apply in a validation study with a
large number of patients. Most importantly, the functional relevance of biomarkers identified may be promising in designing therapeutic
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interventions to influence the course of disease. 
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